Abstract

The ovalbumin-induced (OVA) chronic allergic airways murine model is a well-established model for investigating pre-clinical therapies for chronic allergic airways diseases, such as asthma. Here, we examined the effects of several experimental compounds with potential anti-asthmatic effects including resveratrol (RV), relaxin (RLN), l-sulforaphane (LSF), valproic acid (VPA), and trichostatin A (TSA) using both a prevention and reversal model of chronic allergic airways disease. We undertook a novel analytical approach using focal plane array (FPA) and synchrotron Fourier-transform infrared (S-FTIR) microspectroscopic techniques to provide new insights into the mechanisms of action of these experimental compounds. Apart from the typical biological effects, S-FTIR microspectroscopy was able to detect changes in nucleic acids and protein acetylation. Further, we validated the reduction in collagen deposition induced by each experimental compound evaluated. Although this has previously been observed with conventional histological methods, the S-FTIR technique has the advantage of allowing identification of the type of collagen present. More generally, our findings highlight the potential utility of S-FTIR and FPA-FTIR imaging techniques in enabling a better mechanistic understanding of novel asthma therapeutics.

Details

Title
Investigation of molecular mechanisms of experimental compounds in murine models of chronic allergic airways disease using synchrotron Fourier-transform infrared microspectroscopy
Author
Mazarakis Nadia 1 ; Jitraporn, Vongsvivut 2 ; Bambery, Keith R 2 ; Ververis Katherine 3 ; Tobin, Mark J 2 ; Royce, Simon G 4 ; Samuel Chrishan S 4 ; Snibson, Kenneth J 5 ; Licciardi, Paul V 6 ; Karagiannis, Tom C 7 

 Monash University, Alfred Centre, Epigenomic Medicine Laboratory, Department of Diabetes, Central Clinical School, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); University of Melbourne, Faculty of Veterinary and Agricultural Sciences, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Murdoch Children’s Research Institute, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X) 
 ANSTO Australian Synchrotron, Clayton, Australia (GRID:grid.248753.f) (ISNI:0000 0004 0562 0567) 
 Monash University, Alfred Centre, Epigenomic Medicine Laboratory, Department of Diabetes, Central Clinical School, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
 Monash University, Department of Pharmacology, Monash Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
 University of Melbourne, Faculty of Veterinary and Agricultural Sciences, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 Murdoch Children’s Research Institute, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X); University of Melbourne, Department of Paediatrics, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 Monash University, Alfred Centre, Epigenomic Medicine Laboratory, Department of Diabetes, Central Clinical School, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); University of Melbourne, Department of Clinical Pathology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2424342065
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.